8 weeks versus 12 weeks of sofosbuvir-velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India.

An 8-week sofosbuvir-velpatasvir regimen is non-inferior to 12 weeks for treating non-cirrhotic chronic hepatitis C, achieving over 98% SVR12 success.

• Why it matters: Shorter treatment durations can improve patient adherence, reduce costs, and optimize healthcare resources, addressing the need for effective, shorter HCV therapies in resource-limited settings.
• What they did: A multicentre, randomized trial in India enrolled 880 treatment-naive adults with non-cirrhotic HCV, comparing 8-week versus 12-week regimens, with primary outcome measuring SVR12 rates.
• The result: The 8-week regimen demonstrated comparable efficacy, with SVR12 rates of 98.8% (per-protocol) and 93.5% (intention-to-treat), and no serious adverse events, supporting shorter treatment durations for such patients.